Noble Life Sciences, Inc., a preclinical drug development contract research organization (CRO), announced a partnership with BioFactura, Inc. (Rockville, MD), a developer and provider of proprietary technologies and services for production of biologicals.
The collaboration expands Noble’s CRO services to include the development and production of monoclonal antibody and other protein-based drugs. Through the partnership, Noble becomes the exclusive commercial contract services provider of BioFactura’s technologies and capabilities.